{"DataElement":{"publicId":"3234466","version":"1","preferredName":"Breast Post Neoadjuvant Therapy Response Code","preferredDefinition":"Text code to represent the result of neoadjuvant chemotherapy treatment on sites of disease in breast tissue","longName":"BRST_NEOADJ_RESP_CD","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"3234406","version":"1","preferredName":"Breast Post Neoadjuvant Therapy Response","preferredDefinition":"One of two hemispheric projections of variable size situated in the subcutaneous layer over the pectoralis major muscle on either side of the chest._In medicine, an improvement related to treatment._A bean-shaped organ surrounded by a connective tissue capsule. It is part of the lymphatic system and is found throughout the body._","longName":"BRST_NEOADJ_RESP","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2411756","version":"1","preferredName":"Breast","preferredDefinition":"One of two hemispheric projections of variable size situated in the subcutaneous layer over the pectoralis major muscle on either side of the chest.","longName":"C12971","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast","conceptCode":"C12971","definition":"One of two hemispheric projections of variable size situated in the subcutaneous layer over the pectoralis major muscle on either side of the chest.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0198F493-9F65-1CFD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-25","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-09-25","modifiedBy":"ONEDATA","dateModified":"2005-09-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3228223","version":"1","preferredName":"Post Neoadjuvant Therapy Response","preferredDefinition":"Post; occuring after.:Treatment designed to be used as a first step toward shrinking the cancer and in evaluating response to drugs and other agents. Induction therapy is followed by additional therapy to eliminate whatever cancer remains.:In medicine, an improvement related to treatment.","longName":"C38008:C15665:C50995","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Post","conceptCode":"C38008","definition":"Happening at a time subsequent to a reference time; later in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Neoadjuvant Therapy","conceptCode":"C15665","definition":"Therapy administered prior to the primary treatment for the purpose of making the primary treatment more effective.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A147C0E5-778B-4A7D-E040-BB89AD432370","latestVersionIndicator":"Yes","beginDate":"2011-04-19","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-19","modifiedBy":"ONEDATA","dateModified":"2011-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008563","version":"1","preferredName":"Therapy Results","preferredDefinition":"the results or effects (does not include CTC Adverse Events) of therapeutic agents or procedures administered to the patient.","longName":"TX_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6690D31-4081-494A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-06","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-02-11","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A2ED5D1E-5826-742B-E040-BB89AD4304FD","latestVersionIndicator":"Yes","beginDate":"2011-05-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-10","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3234450","version":"1","preferredName":"Breast Post Neoadjuvant Therapy Response Code","preferredDefinition":"One of two hemispheric projections of variable size situated in the subcutaneous layer over the pectoralis major muscle on either side of the chest._Post; occuring after._Treatment designed to be used as a first step toward shrinking the cancer and in evaluating response to drugs and other agents. Induction therapy is followed by additional therapy to eliminate whatever cancer remains._In medicine, an improvement related to treatment._A system of numbered categories for representation of data.","longName":"BRST_NEOADJ_RESP_CD","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"B5","valueDescription":"No significant response","ValueMeaning":{"publicId":"3234451","version":"1","preferredName":"No significant response","longName":"3234451","preferredDefinition":"No significant response","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A2F0C720-0C04-CE54-E040-BB89AD43681B","latestVersionIndicator":"Yes","beginDate":"2011-05-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A2F0C720-0C1D-CE54-E040-BB89AD43681B","beginDate":"2011-05-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-10","modifiedBy":"ONEDATA","dateModified":"2011-05-10","deletedIndicator":"No"},{"value":"B4","valueDescription":"Partial Response (<50% reduction in tumor cellularity)A","ValueMeaning":{"publicId":"3234452","version":"1","preferredName":"Partial Response (<50% reduction in tumor cellularity)A","longName":"3234452","preferredDefinition":"Partial Response (<50% reduction in tumor cellularity)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A2F0C720-0C27-CE54-E040-BB89AD43681B","latestVersionIndicator":"Yes","beginDate":"2011-05-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A2F0C720-0C40-CE54-E040-BB89AD43681B","beginDate":"2011-05-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-10","modifiedBy":"ONEDATA","dateModified":"2011-05-10","deletedIndicator":"No"},{"value":"B3","valueDescription":"Good Response (>50% reduction in tumor cellularity)","ValueMeaning":{"publicId":"3234453","version":"1","preferredName":"Good Response (>50% reduction in tumor cellularity)","longName":"3234453","preferredDefinition":"Good Response (>50% reduction in tumor cellularity)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A2F0C720-0C4A-CE54-E040-BB89AD43681B","latestVersionIndicator":"Yes","beginDate":"2011-05-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A2F0C720-0C63-CE54-E040-BB89AD43681B","beginDate":"2011-05-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-10","modifiedBy":"ONEDATA","dateModified":"2011-05-10","deletedIndicator":"No"},{"value":"B2","valueDescription":"Subtotal Response (>95% reduction in tumor cellularity)","ValueMeaning":{"publicId":"3234454","version":"1","preferredName":"Subtotal Response (>95% reduction in tumor cellularity)","longName":"3234454","preferredDefinition":"Subtotal Response (>95% reduction in tumor cellularity)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A2F0C720-0C6D-CE54-E040-BB89AD43681B","latestVersionIndicator":"Yes","beginDate":"2011-05-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A2F0C720-0C86-CE54-E040-BB89AD43681B","beginDate":"2011-05-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-10","modifiedBy":"ONEDATA","dateModified":"2011-05-10","deletedIndicator":"No"},{"value":"B1b","valueDescription":"No residual invasive cancer but residual in situ cancer","ValueMeaning":{"publicId":"3234455","version":"1","preferredName":"No residual invasive cancer but residual in situ cancer","longName":"3234455","preferredDefinition":"No residual invasive cancer but residual in situ cancer","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A2F0C720-0C90-CE54-E040-BB89AD43681B","latestVersionIndicator":"Yes","beginDate":"2011-05-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A2F0C720-0CA9-CE54-E040-BB89AD43681B","beginDate":"2011-05-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-10","modifiedBy":"ONEDATA","dateModified":"2011-05-10","deletedIndicator":"No"},{"value":"B1a","valueDescription":"No residual invasive or in situ cancer","ValueMeaning":{"publicId":"3234456","version":"1","preferredName":"No residual invasive or in situ cancer","longName":"3234456","preferredDefinition":"No residual invasive or in situ cancer","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A2F0C720-0CB3-CE54-E040-BB89AD43681B","latestVersionIndicator":"Yes","beginDate":"2011-05-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A2F0C720-0CCC-CE54-E040-BB89AD43681B","beginDate":"2011-05-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-10","modifiedBy":"ONEDATA","dateModified":"2011-05-10","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008563","version":"1","preferredName":"Therapy Results","preferredDefinition":"the results or effects (does not include CTC Adverse Events) of therapeutic agents or procedures administered to the patient.","longName":"TX_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6690D31-4081-494A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-06","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-02-11","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3234449","version":"1","preferredName":"Breast Post Neoadjuvant Therapy Response Code","preferredDefinition":"One of two hemispheric projections of variable size situated in the subcutaneous layer over the pectoralis major muscle on either side of the chest.:Post; occuring after.:Treatment designed to be used as a first step toward shrinking the cancer and in evaluating response to drugs and other agents. Induction therapy is followed by additional therapy to eliminate whatever cancer remains.:In medicine, an improvement related to treatment.:A system of numbered categories for representation of data.","longName":"3234449v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast","conceptCode":"C12971","definition":"One of two hemispheric projections of variable size situated in the subcutaneous layer over the pectoralis major muscle on either side of the chest.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Post","conceptCode":"C38008","definition":"Happening at a time subsequent to a reference time; later in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Neoadjuvant Therapy","conceptCode":"C15665","definition":"Therapy administered prior to the primary treatment for the purpose of making the primary treatment more effective.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A2F0C720-0BE0-CE54-E040-BB89AD43681B","latestVersionIndicator":"Yes","beginDate":"2011-05-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-10","modifiedBy":"ONEDATA","dateModified":"2011-05-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A2F0C720-0BF1-CE54-E040-BB89AD43681B","latestVersionIndicator":"Yes","beginDate":"2011-05-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-10","modifiedBy":"ONEDATA","dateModified":"2011-05-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2812367","version":"1","longName":"caBIG","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]},{"publicId":"2183535","version":"1","longName":"Clinical Trial Mgmt Systems","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2812625","version":"1","longName":"CTMS C3D Adopter Sites","context":"NCIP"},{"publicId":"2811715","version":"1","longName":"Duke University","context":"NCIP"},{"publicId":"2812724","version":"1","longName":"Duke U New CDEs","context":"NCIP"}]},{"publicId":"3886752","version":"1","longName":"For Review","context":"DCI","ClassificationSchemeItems":[{"publicId":"3891931","version":"1","longName":"For Review","context":"DCI"}]}],"AlternateNames":[{"name":"DCI","type":"USED_BY","context":"DCI"}],"ReferenceDocuments":[{"name":"Response in Breast","type":"Preferred Question Text","description":"Response in Breast","url":null,"context":"NCIP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A2F0C720-0DAF-CE54-E040-BB89AD43681B","latestVersionIndicator":"Yes","beginDate":"2011-05-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-10","modifiedBy":"REEVESD","dateModified":"2015-05-19","changeDescription":"Curated to support Duke University clinical trial","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}